OKYO Pharma (OKYO) vs Oncolytics Biotech (ONCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Oncolytics Biotech (ONCY) over the past year, losing 37.9% versus a loss of 57.5%. OKYO Pharma is the larger company by market cap ($72.9 million vs $71.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKYO | ONCY |
|---|---|---|
| Share price | $1.39 | $0.5444 |
| Market cap | $72.95M | $71.38M |
| 1-day change | -2.73% | -8.63% |
| YTD return | -32.85% | -37.43% |
| 1-year return | -37.95% | -57.47% |
| 5-year return | — | -75.48% |
| EPS (TTM) | $-0.24 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $1.32 |
| 52-week low | $1.27 | $0.54 |
| Distance from 52-week high | -56.56% | -58.76% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +499.28% | +662.31% |
| Average volume | 94.59K | 1.08M |
| Shares outstanding | 52.48M | 131.12M |
| Employees | 5 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed ONCY by 19.5 percentage points over the past year.
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
About Oncolytics Biotech
ONCY stock →Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer.
Healthcare · Biotechnology · 29 employees
OKYO vs ONCY FAQ
Which is bigger, OKYO Pharma or Oncolytics Biotech?
OKYO Pharma (OKYO) is larger, with a market capitalization of $72.95M compared with $71.38M for Oncolytics Biotech (ONCY).
Which stock has performed better over the past year, OKYO or ONCY?
OKYO returned -37.95% over the past 12 months, compared with -57.47% for ONCY (price return, excluding dividends). Past performance does not predict future results.
Are OKYO Pharma and Oncolytics Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.